Skip to content

Nutrient Uptake During Continuous Enteral Feeding

Uptake of Glucose and Phenylalanine From Continuous Enteral Nutrition in Healthy and Critically Ill Persons

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05628844
Enrollment
20
Registered
2022-11-29
Start date
2023-01-01
Completion date
2026-12-31
Last updated
2022-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness

Keywords

Continuous enteral feeding, Gastric volume, Intestinal absorption, Enteral nutrition, Nutritional support

Brief summary

Continuous enteral nutrition is used to feed patients in intensive care who are unable to eat normally. The goal of this observational study is to learn about the uptake of nutrients from feeding formula. The study method will first be applied in healthy persons to establish workability and normal values, then in patients in the intensive care unit to learn how nutrient uptake is affected by critical illness. The main questions this study aims to answer are: * what is the time course of uptake of phenylalanine (an amino acid) and glucose (a sugar) from enteral feeding formula given continuously over several hours * what is the time course of the filling volume of the stomach during continuous enteral feeding Participants receive feeding formula through a nasogastric feeding tube and blood samples are taken at short intervals to analyse uptake of nutrients into blood. Simultaneously, the filling volume of the stomach is measured by gastric ultrasound.

Detailed description

Background The investigators have previously studied the uptake of dietary isotope-labeled phenylalanine and plasma amino acid concentrations in critically ill patients and healthy subjects. During continuous feeding, uptake was unexpectedly found to be highly variable over time. Due to infrequent sampling, the time course of variability could not be modeled mathematically. Also, the underlying physiological mechanisms remain unclear, though it is hypothesized that gastric emptying is a major factor determining temporal variability. The study here described is a follow-up that includes serial abdominal ultrasound studies to measure gastric emptying, additional indicators/tracers to determine more detail of uptake vs. digestion/transport/metabolism, and makes use of more frequent sampling to allow for detailed mathematical modeling of temporal variability. Experimental protocol ICU patients: * Standard care and treatment as per clinical routines * Pre-experiment ongoing nutrition for ≥ 6 hrs by nasogastric feeding tube or gastrostomy (not postpyloric) * Bed rest during experiment as feasible Healthy subjects * Keep dietary and training habits for ≥ 2 days before experiment start * Overnight fast * Bed rest during experiment as feasible * Nasogastric feeding tube * Arterial line in radial or ulnar artery Nutrition, sampling, measurements * Experimental nutrition by continuous infusion for 10 hrs * Infusion rate corresponding to 25 kcal/kg body weight/day (calculated including metabolizable tracers/indicators) * Arterial blood sampling (à 1 ml) every 5 min in pilot study (may adjust to 10 or 15 min depending on results of pilot study) * Serial abdominal ultrasound for determination of gastric volume (pilot study will determine how often) Experimental nutrition * Commercially available feeding formula for ICU use (Fresubin® HP Energy or similar) with added phenylalanine and glucose indicators * Intrinsically labeled protein: 13C-L-phenylalanine intrinsically labeled milk protein * Nonmetabolisable phenylalanine analogue: D-phenylalanine * Free amino acid tracer: stable isotope-labeled phenylalanine tracer (2H5-L-Phe) * Non-metabolizable glucose analogue: 3-O-Methyl-d-glucose (3-OMG) * Free glucose tracer: isotope labeled D-glucose Analyses * arterial plasma amino acid and glucose tracers as above * arterial plasma 3-OMG * arterial plasma aminograms * arterial plasma glucose, insulin, c peptide

Interventions

Enteral nutrition by continuous infusion for 10 hrs at a dose corresponding to 25 kcal/kg body weight/day

Sponsors

Karolinska University Hospital
CollaboratorOTHER
Karolinska Institutet
CollaboratorOTHER
Felix Liebau
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

(ICU patients): \- stable enteral nutrition of \>80% of measured or calculated energy expenditure by nasogastric feeding tube or gastrostomy

Exclusion criteria

(ICU patients): * enteral nutrition by postpyloric route such as jejunostomy or postpyloric tube * remaining ICU stay expected \< 12 hrs * ongoing bleeding that requires surgery/intervention or transfusion of \> 2 units red cells/24 hrs * inability to use feeding tube or arterial line Inclusion Criteria (healthy subjects): \- healthy volunteer

Design outcomes

Primary

MeasureTime frameDescription
Glucose and phenylalanine indicators0-10 hoursTime series of isotopic and non-isotopic indicators of glucose and phenylalanine from enteral nutrition
Gastric volume0-10 hoursTime series of gastric volume

Secondary

MeasureTime frameDescription
Plasma metabolites0-10 hoursTime series of plasma aminograms, glucose, insulin and c peptide

Contacts

Primary ContactFelix Liebau, MD PhD
felix.liebau@regionstockholm.se
Backup ContactOlav Rooyackers, Prof Phd
olav.rooyackers@ki.se+46702069227

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026